Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies

Paul Monagle, Anthonie W. A. Lensing*, Kirstin Thelen, Ida Martinelli, Christoph Male, Amparo Santamaria, Elena Samochatova, Riten Kumar, Susanne Holzhauer, Paola Saracco, Paolo Simioni, Jeremy Robertson, Gernot Grangl, Jacqueline Halton, Phillip Connor, Guy Young, Angelo C. Molinari, Ulrike Nowak-Goettl, Gili Kenet, Stefanie KapsaStefan Willmann, Akos F. Pap, Michael Becka, Teresa Twomey, Jan Beyer-Westendorf, Martin H. Prins, Dagmar Kubitza, Investigators, EJP

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E500-E509
Number of pages10
JournalThe Lancet Haematology
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • DEEP-VEIN THROMBOSIS
  • REPORTED TREATMENT SATISFACTION
  • XA INHIBITOR RIVAROXABAN
  • ORAL RIVAROXABAN
  • ATRIAL-FIBRILLATION
  • STANDARD THERAPY
  • DEFINITION

Cite this

Monagle, P., Lensing, A. W. A., Thelen, K., Martinelli, I., Male, C., Santamaria, A., Samochatova, E., Kumar, R., Holzhauer, S., Saracco, P., Simioni, P., Robertson, J., Grangl, G., Halton, J., Connor, P., Young, G., Molinari, A. C., Nowak-Goettl, U., Kenet, G., ... Investigators, EJP (2019). Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. The Lancet Haematology , 6(10), E500-E509. https://doi.org/10.1016/S2352-3026(19)30161-9